Close Menu

payor coverage

The company said the number of lives now covered for EndoPredict has gone up to 109 million.

Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues. 

The company said it now has payor coverage for more than 130 million individuals.

The company obtained out-of-state provider status from California's Medicaid program for its OVA1 test, giving it access to more than 12 million patients. 

The firm said that the new coverage for its Afirma thyroid cancer test makes it a medically necessary benefit for nearly 24 million Blues plan members.

Starting Feb. 15, Aetna members will be able to access NxGen MDx's genetic screening and noninvasive prenatal testing as an in-network benefit. 

The coverage decision provides Humana's 13 million members with access to the test, which provides a numerical score to assess the risk of disease recurrence.

Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

With a recent draft guidance from Medicare contractor Palmetto, and $6.1 million in new funding, Indi hopes to launch the test in the next six to nine months.

EndoPredict is a kit-based RNA expression test that evaluates 12 genes to assess the aggressiveness of breast cancer on a molecular level, and is set to launch in the US this year.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.